Development of High-Alert Medication List Based on Expert Consensus and Healthcare Workers Investigation
LIU Fang1,3, ZHANG Ting1,3, ZHANG Xiao-le1,3, ZHU Zhu2,3, ZHAI Suo-di1,3
1. Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China;
2. Peking Union Medical College Hospital, Beijing 100730, China;
3. Medication Safety Expert Group, Hospital Pharmacy Committee, Chinese Pharmaceutical Association, Beijing 100191, China
OBJECTIVE To develop high-alert medication list that complies with Chinese medication practice. METHODS The study was organized by the Group of Medication Safety Experts, Hospital Pharmacy Committee, Chinese Pharmaceutical Association. Selection criteria for high-alert drugs were developed with Delphi consensus among 18 medication safety experts, then two rounds of survey followed. The first round contained open-ended questions, by which the respondents were asked to nominate high-alert medications in addition to ISMP list according to the selection criteria. The new nominations were classified and screened by the experts group to get a preliminary list. The second round was grading scale survey. The healthcare workers who responded to the first round survey were asked to grade on their familiarity to and the risk degree of each medication in the preliminary list. With familiarity as the weight, the weighted risk averages and standard deviations of each medicine were calculated to decide if the medication was included in the high alert medication list or not. RESULTS Selection criteria of high alert medications were developed, which contains 6 items and were used in the first round survey. Totally 782 healthcare workers in 23 hospitals responded to the survey. Through two rounds of survey, 24 classes and 14 specific medications were included in the final list. Compared with ISMP list, the newly added were two more classes, including reproductive toxic drugs and intravenous theophylline, 4 more specific medications, including topical potassium permanganate, 5 mg·mL-1 atrophine injection, lyophilizing thrombin powder and arsenic trioxide for injection. CONCLUSION A high-alert medication list is developed with two more classed and four more drugs newly adding to the ISMP list, which complies better with Chinese healthcare practice.
����, ����, ������, ����, ������. ����ר�ҹ�ʶ��ҽ����Ա����ĸ߾�ʾҩƷĿ¼����[J]. �й�ҩѧ��־, 2018, 53(17): 1523-1528.
LIU Fang, ZHANG Ting, ZHANG Xiao-le, ZHU Zhu, ZHAI Suo-di. Development of High-Alert Medication List Based on Expert Consensus and Healthcare Workers Investigation. Chinese Pharmaceutical Journal, 2018, 53(17): 1523-1528.
Institute for Safe Medication Practices. ISMP��s list of high-alert medications . 2015-07-15. . http://www.ismp.org/tools/highalertmedicationLists.asp.
TANG S F, WANG X, ZHANG Y, et al. Analysis of high alert medication knowledge of medical staff in Tianjin: a convenient sampling survey in China. J Huazhong Univ(Sci Med)(���пƼ���ѧѧ��:ҽѧ��),2015,35(2):176-182.
Medication Safety Expert Group, Hospital Pharmacy Committee, Chinese Pharmaceutical Association. China high-alert medication list 2015 . 2015-07-15. . http://www.cpahp.org.cn/Announce.asp?ChannelID=0&ID=29/.
LIU S Q, LIU W Y, YANG Y. Research on risk control measures of isovitamin A acid after market in US. China Pharmacov (�й�ҩ�ﾯ��), 2015,12(12):748-752.
UHL K, COX E, ROGAN R,et al. Thalidomide use in the US:experience with pregnancy testing in the STEPS program. Drug Safe, 2006,29(4):321-329.
Asthma group, respiratory diseases branch of Chinese Medical Association. Guideline for prevention and treatment of asthma (2016 Edition). Chin J Tuberc Resp Dis (�л���˺ͺ�����־), 2016,39(9):675-697.
GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD .2017-01-03. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/.
ZHU W M. New progress and rational application of drugs for asthma. Chin J Clin Rat Drug Use (�ٴ�������ҩ��־), 2014,7(8):124-125.
JIN H H, MO L. Lessons from clinical overuse of atropine. Pract Med(ʵ��ҽ��), 2001,8(7):509-510.
XIA W B, ZHANG X L. Incorrect dosage of look-alike drugs. Chin Med Trib(�й�ҽѧ��̳��),2012-01-20(A10).
HUO M. Rescue and nursing care of 11 children with potassium permanganate poisoning. Chin J Nurs (�л�������־),2010,47(2):173-174.
KARTHIK R, VEERENDRANATH H P, WALI S, et al. Suicidal ingestion of potassium permanganate crystals:a rare encounter.Toxi Int, 2014,21(3):331-334.
HU N. Lyophilizing thrombin powder was mistaken as injection:one case report. Chin Rural Med(�й����ҽҩ), 2010,17(8):39-39.
GUI H X, GUO J. A case report of mistakenly vein injecting Lyophilizing Thrombin Powder. Primary Med Care Forum (����ҽѧ��̳), 2013,17(14):1904-1904.
ZHANG J Y, SUN G B, WANG M, et al. Research advances on cardiac toxicity of arsenic trioxide. Chin Pharmacol Bull (�й�ҩ��ѧͨ��),2016,32(9):1194-1198.
OTERO M J, MORENO-GÓMEZ A M, SANTOS-RAMOS B, et al. Developing a list of high-alert medications for patients with chronic diseases. Eur J Intern Med, 2014,25(10):900-908.
TYYNISMAA L, HONKALA A, AIRAKSINEN M, et al. Identifying high-alert medications in a university hospital by applying data from the medication error reporting system . J Patient Saf, 2017-06-01. https://insights.ovid.com/pubmed?pmid=28574956.
BATAILLE J, PROT-LABARTHE S, BOURDON O, et al. High-alert medications in a French pediatric university hospital. J Eval Clin Pract, 2015,21(2):262-270.
MAASKANT J M, ESKES A, VAN RIJN-BIKKER P, et al. High-alert medications for pediatric patients:an international modified Delphi study. Expert Opin Drug Safe, 2013,12(6):805-814.
YAN H, LI Y, SUN S G. Screening method of high-alert drugs list in general hospital of Beijing military command. J China Pharm(�й�ҩ��),2013,24(25):2340-2344.
WANG C X,WANG X L,LI X L, et al. Development of a list of high-alert medications for the Chinese children.Adverse Drug React J(ҩ�ﲻ����Ӧ��־),2017,19(1):10-16.
SUN S G, SUN X D, YAN H, et al. Discussion and research on the management of high-risk Chinese medicine injection in hospital. China Med(�й�ҽҩ),2012,7(8):1050-1052.
LI X L, YAN S Y, WANG Y Q, et al. Analysis of 1 165 cases of medication errors in 22 hospitals in Beijing. Adverse Drug React J(ҩ�ﲻ����Ӧ��־), 2013,15(2):64-68.
ENGELS M J, CIARKOWSKI S L. Nursing, pharmacy, and prescriber knowledge and perceptions of high-alert medications in a large, academic medical hospital. Hosp Pharm, 2015,50(4):287-295.
KAO L C. Building a "high-alert/high risk medications reminder system" to improve patient safety. Value Health, 2014,17(7):425-425.
LEE J, HAN H, OCK M, et al. Impact of a clinical decision support system for high-alert medications on the prevention of prescription errors. Int J Med Inform, 2014,83(12):929-940.
KHOO A L, TENG M, LIM B P, et al. A multicenter, multidisciplinary, high-alert medication collaborative to improve patient safety:the Singapore experience. Jt Comm J Qual Patient Saf, 2013,39(5):205-212.
PENG T R, WU T W. The experience of management of high-alert medications. Am J Med Qua, 2017,32(5):571-571.
CAJANDING J M R. Administering and monitoring high-alert medications in acute care. Nurs Stand, 2017,31(47):42-52.
Medication Safety Expert Group, Hospital Pharmacy Committee, Chinese Pharmaceutical Association. High alert medication grading management strategy and recommended catalogue . 2012-03-31. http://www.cpahp.org.cn/ccyyf/news/201203/1435.htm.
YANG J, HE F, CHEN Z, et al. Discussion on quality control of chemotherapy in cancer hospital. Chin Pharm J(�й�ҩѧ��־), 2016,51 (24):2146-2149.
CHEN S L, QIAN Z Z. Study on safety and verification of Chinese medicine. Chin Pharm J (�й�ҩѧ��־), 2015,50 (17):1467-1468.